Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Innate Pharma S.A.NASDAQ: IPHA

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit declines year over year

Q4 FY2025 gross profit of €18.45M fell 37.2% year over year. Over 3 fiscal years it compounded at -22.6% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€18.45M— QoQ
Last fiscal yearDec 2025
€2.79M-77.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.2%——
1 year-77.9%——
3-year CAGR-22.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

EUR · from the income statement

Latest · FY2025
2.79M EUR
Year-over-year change
-77.9%

Gross Profit vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -77.9% is the lowest of 7, against a peer median of +95.4%.
  • Gross profit amounts to 100.0% of revenue for IPHA, versus a peer median of 94.8%.
IPHA Competitors
Gross Profit for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$63.98M USD+230.5%+113.5%88.1%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.01M USD+150.7%—94.9%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.69M USD—-34.1%94.7%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$289K USD+75.2%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$11.06M USD-20.7%+15.4%2105.7%
Peer median (excluding IPHA) —+95.4%+15.4%94.8%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.